All In Biotech

NDA 012750 · Bausch

Librax

Chlordiazepoxide Hydrochloride, Clidinium Bromide · Oral

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1966

Sep 1, 1966

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

2 Phase 3, 0 recruiting

FAERS reports

1,925

1,089 serious, 68 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS and PRECAUTIONS , Drug Interactions ). • The use of benzodiazepines, including chlordiazepoxide hydrochloride, a component of Librax, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an...

What it is approved for

From the label in effect Jan 13, 2023.

INDICATIONS AND USAGE: Librax is indicated to control emotional and somatic factors in gastrointestinal disorders. Librax may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 1, 1966 Original approval · Type 4 - New Combination
1 products under this application
  • LIBRAX · CHLORDIAZEPOXIDE HYDROCHLORIDE 5MG; CLIDINIUM BROMIDE 2.5MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlordiazepoxide" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea182
  • nausea182
  • fatigue169
  • drug ineffective141
  • pain132
  • headache120
  • abdominal pain112
  • dizziness108
  • vomiting98
  • asthenia97
  • arthralgia95
  • weight decreased95

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200481
200581
200660
200774
200875
200977
201084
201198
2012122
2013108
201491
2015194
2016185
2017131
201891
201959
202051
202160
202245
202349
202457
202526
202626

Recalls

1 FDA enforcement reports for this application.

  • Apr 18, 2015 · Class III · Terminated

    Failed Impurities/Degradation Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Librax (Chlordiazepoxide/Clidinium Br)

2024 spending

$2.4M

Beneficiaries

351

1,011 claims

Per beneficiary

$6,821

$14.81 per unit

View as table
YearSpending
2020$6,601,655
2021$5,018,637
2022$3,680,666
2023$3,034,242
2024$2,394,191

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 234 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.